Aug. 2 at 6:52 PM
"Heads up alert! Upcoming earnings on Thursday, 8/7/2025 for
$NTRA
Bullish (8.2)
Natera, Inc.
(NASDAQ: NTRA) is demonstrating strong momentum in the precision medicine and cell-free DNA sectors, cementing its position as a formidable player in the rapidly growing genetic testing market.
Recent strategic initiatives, such as the launch of the TEODOR trial and the presentation of new data at prominent conferences, reinforce Natera’s commitment to innovation and expansion in oncology and transplant diagnostics.
Natera's forward P/E ratio stands at a significant -130.98, which, while indicative of current net losses, places heavy emphasis on anticipated future growth.
The company's recent stock price of
$135.81 against Evercore ISI’s
$170 price target reflects investor optimism, despite the lack of current profitability.
Analysts are particularly bullish on Natera’s strategic positioning, as evidenced by its ""Outperform"" rating and the reiteration of a
$220 price target post-Medicare coverage adjustments for its WGS Signatera assay.
As Natera continues to innovate with trials like Signatera in early-stage breast cancer and Prospera’s kidney transplant monitoring, its potential for revenue growth remains robust.
The non-invasive prenatal testing market, in which Natera is a key player, is projected to grow at a 13.55% CAGR, reaching
$11.36 billion by 2033, driven by technological advancements and increasing health awareness.
Compared to its peers, Natera's growth trajectory is bolstered by a strong focus on clinical validation and market expansion, underscoring its bullish outlook.
Natera is scheduled to release its second-quarter earnings on August 7, 2025.
Historically, Natera has shown resilience in maintaining growth momentum, often surpassing market expectations.
Analysts anticipate continued robust performance, driven by recent strategic initiatives and expanding market opportunities.
The company's Q2 results are expected to reflect ongoing advancements in its product offerings and strategic partnerships, potentially impacting stock valuation positively.
The analyst consensus estimates point towards steady revenue growth, which, if met or exceeded, could further solidify investor confidence and potentially drive the stock higher post-earnings announcement.
The healthcare and biotechnology sectors, to which Natera belongs, have been experiencing notable growth, driven by innovation and increasing demand for precision medicine.
The sector is currently outperforming broader market indices, benefiting from heightened interest in genetic testing and personalized healthcare solutions.
Companies within this sector are focusing on expanding their product portfolios and demonstrating clinical efficacy, positioning themselves for long-term growth amidst evolving healthcare landscapes.
- Funds were net buyers of
$NTRA during the previous reporting quarter.
- Funds with large holdings in
$NTRA include:
- Farallon Capital Management LLC, MV:
$643MM. Fund Rank: 70%
www.faralloncapital.com
- Duquesne Family Office LLC, MV:
$481MM. Fund Rank: 96%
www.duquesne.com
- Gilder Gagnon Howe & Co LLC , MV:
$165MM. Fund Rank: 88%
www3.gghc.com
- ARK Investment Management LLC, MV:
$133MM. Fund Rank: 85%
www.ark-invest.com
- GW&K Investment Management LLC, MV:
$47MM. Fund Rank: 75%
- Last 10 days performance: -4%
- Last 30 days performance: -17%
- Last 90 days performance: -15%
Some of the latest news articles:
- Title: Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
Publication Date: 8/1/2025 11:00:00 AM, Source: yahoo
URL: https://finance.yahoo.com/news/natera-highlights-latest-prospera-data-110000666.html?.tsrc=rss
- Title: High Growth Tech Stocks in the US for July 2025
Publication Date: 7/31/2025 11:38:11 AM, Source: yahoo
URL: https://finance.yahoo.com/news/high-growth-tech-stocks-us-113811909.html?.tsrc=rss
- Title: Natera to Report Its Second Quarter Results on August 7, 2025
Publication Date: 7/31/2025 11:00:00 AM, Source: yahoo
URL: https://finance.yahoo.com/news/natera-report-second-quarter-results-110000286.html?.tsrc=rss
- Title: Evercore ISI Initiates Coverage on Natera (NTRA) with Outperform Rating
Publication Date: 7/31/2025 4:21:15 AM, Source: yahoo
URL: https://finance.yahoo.com/news/evercore-isi-initiates-coverage-natera-042115701.html?.tsrc=rss
Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal."
